Suppr超能文献

在假定的癌症干细胞/祖细胞中测量多药耐药转运蛋白活性。

Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.

作者信息

Donnenberg Vera S, Meyer E Michael, Donnenberg Albert D

机构信息

Hillman Cancer Center, Pittsburgh, PA, USA.

出版信息

Methods Mol Biol. 2009;568:261-79. doi: 10.1007/978-1-59745-280-9_17.

Abstract

Multiple drug resistance, mediated by the expression and activity of ABC-transporters, is a major obstacle to antineoplastic therapy. Normal tissue stem cells and their malignant counterparts share MDR transporter activity as a major mechanism of self-protection. Although MDR activity is upregulated in response to substrate chemotherapeutic agents, it is also constitutively expressed on both normal tissue stem cells and a subset of tumor cells prior to the initiation of therapy, representing a built-in obstacle to therapeutic ratio. Constitutive and induced MDR activity can be detected in cellular subsets of disaggregated tissues, using the fluorescent substrates Rhodamine 123 and Hoechst 33342 for ABCB1 (also known as P-gp and MDR1) and ABCG2 (BCRP1). In this chapter, we will describe the complete procedure for the detection of MDR activity, including: (1) Preparing single-cell suspensions from tumor and normal tissue specimens; (2) An efficient method to perform cell surface marker staining on large numbers of cells; (3) Flow cytometer setup and controls; (4) Simultaneous measurement of Hoechst 33342 and Rhodamine123 transport; and (5) Data acquisition and analysis.

摘要

由ABC转运蛋白的表达和活性介导的多药耐药性是抗肿瘤治疗的主要障碍。正常组织干细胞及其恶性对应物具有多药耐药转运蛋白活性,这是自我保护的主要机制。尽管多药耐药活性会因底物化疗药物而上调,但在治疗开始前,它在正常组织干细胞和一部分肿瘤细胞上也呈组成性表达,这是治疗指数的一个内在障碍。使用荧光底物罗丹明123和Hoechst 33342检测ABCB1(也称为P-糖蛋白和MDR1)和ABCG2(BCRP1),可以在解离组织的细胞亚群中检测到组成性和诱导性多药耐药活性。在本章中,我们将描述检测多药耐药活性的完整程序,包括:(1)从肿瘤和正常组织标本制备单细胞悬液;(2)对大量细胞进行细胞表面标志物染色的有效方法;(3)流式细胞仪设置和对照;(4)同时测量Hoechst 33342和罗丹明123的转运;以及(5)数据采集和分析。

相似文献

1
Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.
Methods Mol Biol. 2009;568:261-79. doi: 10.1007/978-1-59745-280-9_17.
4
Application of JC1 for non-toxic isolation of cells with MDR transporter activity by flow cytometry.
PLoS One. 2017 Apr 5;12(4):e0174905. doi: 10.1371/journal.pone.0174905. eCollection 2017.
6
Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
J Ethnopharmacol. 2017 May 5;203:110-119. doi: 10.1016/j.jep.2017.03.051. Epub 2017 Mar 28.
7
β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Phytomedicine. 2016 Mar 15;23(3):316-23. doi: 10.1016/j.phymed.2016.01.008. Epub 2016 Feb 6.
8
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Cancer Lett. 2018 May 1;421:186-198. doi: 10.1016/j.canlet.2018.01.021. Epub 2018 Jan 11.

引用本文的文献

2
Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions?
J Cancer Metastasis Treat. 2019;5. doi: 10.20517/2394-4722.2019.13. Epub 2019 May 14.
3
Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment.
Onco Targets Ther. 2019 Feb 27;12:1539-1552. doi: 10.2147/OTT.S191317. eCollection 2019.
4
VSV based virotherapy in ovarian cancer: the past, the present and …future?
J Cancer. 2017 Jul 22;8(12):2369-2383. doi: 10.7150/jca.19473. eCollection 2017.
6
The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.
Ann Thorac Surg. 2017 Jul;104(1):321-328. doi: 10.1016/j.athoracsur.2017.01.091. Epub 2017 May 9.
7
Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.
Oncotarget. 2017 May 9;8(19):31977-31992. doi: 10.18632/oncotarget.16667.
8
Human pancreatic cancer progression: an anarchy among CCN-siblings.
J Cell Commun Signal. 2016 Sep;10(3):207-216. doi: 10.1007/s12079-016-0343-9. Epub 2016 Aug 19.
9
What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment.
Cancer Inform. 2015 Feb 24;14(Suppl 2):25-36. doi: 10.4137/CIN.S17294. eCollection 2015.
10
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.
J Cancer. 2014 Mar 16;5(5):301-10. doi: 10.7150/jca.8610. eCollection 2014.

本文引用的文献

1
Cancer stem cells are enriched in the side population cells in a mouse model of glioma.
Cancer Res. 2008 Dec 15;68(24):10051-9. doi: 10.1158/0008-5472.CAN-08-0786.
2
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.
3
Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
Endocrinology. 2008 Mar;149(3):1314-22. doi: 10.1210/en.2007-1001. Epub 2007 Dec 6.
4
Tumorigenic epithelial stem cells and their normal counterparts.
Ernst Schering Found Symp Proc. 2006(5):245-63. doi: 10.1007/2789_2007_054.
5
Rare-event analysis in flow cytometry.
Clin Lab Med. 2007 Sep;27(3):627-52, viii. doi: 10.1016/j.cll.2007.05.013.
7
Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents.
J Control Release. 2007 Oct 8;122(3):385-91. doi: 10.1016/j.jconrel.2007.05.005. Epub 2007 May 13.
8
Kinetic analyses as a critical parameter in defining the side population (SP) phenotype.
Exp Cell Res. 2007 May 15;313(9):1921-6. doi: 10.1016/j.yexcr.2007.02.025. Epub 2007 Mar 12.
9
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53. doi: 10.1073/pnas.0611682104. Epub 2007 Feb 27.
10
Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport.
Oncogene. 2007 Aug 16;26(38):5674-9. doi: 10.1038/sj.onc.1210356. Epub 2007 Mar 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验